Skip to main content
Log in

Treating hypercholesterinemia in a patient with maternally inherited diabetes and deafness (MIDD) by the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab

  • Case Report
  • Published:
Acta Diabetologica Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Availability of data and material

Data are available on request from the authors.

References

  1. Robinson KN, Terrazas S, Giordano-Mooga S, Xavier NA (2020) The role of heteroplasmy in the diagnosis and management of maternally inherited diabetes and deafness. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 26:241–246. https://doi.org/10.4158/EP-2019-0270

    Article  Google Scholar 

  2. Zhu J, Yang P, Liu X et al (2017) The clinical characteristics of patients with mitochondrial tRNA Leu(UUR)m.3243A > G mutation: compared with type 1 diabetes and early onset type 2 diabetes. J Diabetes Complicat 31:1354–1359. https://doi.org/10.1016/j.jdiacomp.2017.04.001

    Article  Google Scholar 

  3. Naing A, Kenchaiah M, Krishnan B, et al. (2014) Maternally inherited diabetes and deafness (MIDD): diagnosis and management. J Diabetes Complicat 28:542–546. https://doi.org/10.1016/j.jdiacomp.2014.03.006

    Article  Google Scholar 

  4. Ganda OP, Plutzky J, Sanganalmath SK, et al. (2018) Efficacy and safety of alirocumab among individuals with diabetes mellitus and atherosclerotic cardiovascular disease in the ODYSSEY phase 3 trials. Diabetes Obes Metab 20:2389–2398. https://doi.org/10.1111/dom.13384

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Leiter LA, Cariou B, Müller-Wieland D, et al. (2017) Efficacy and safety of alirocumab in insulin-treated individuals with type 1 or type 2 diabetes and high cardiovascular risk: the ODYSSEY DM-INSULIN randomized trial. Diabetes Obes Metab 19:1781–1792. https://doi.org/10.1111/dom.13114

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Bernd Schultes.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article belongs to the topical collection Pregnancy and Diabetes, managed by Antonio Secchi and Marina Scavini.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schultes, B., Ernst, B. & Schmid, S.M. Treating hypercholesterinemia in a patient with maternally inherited diabetes and deafness (MIDD) by the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor alirocumab. Acta Diabetol 58, 1575–1577 (2021). https://doi.org/10.1007/s00592-021-01776-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00592-021-01776-w

Keywords

Navigation